Is Now The Time To Buy WM Morrison Supermarkets PLC, Cobham plc Or Hikma Pharmaceuticals Plc?

WM Morrison Supermarkets PLC (LON:MRW), Cobham plc (LON:COB) and Hikma Pharmaceuticals Plc (LON:HIK) have all issued key trading updates this week.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Do this week’s trading updates improve the buy case for Wm Morrison Supermarkets (LSE: MRW), Cobham (LSE: COB) or Hikma Pharmaceuticals (LSE: HIK)?

Morrisons

Sales at Morrisons fell by 2.6% during the third quarter, on a like-for-like basis. This headline figure from the group’s third-quarter trading statement triggered a 3.5% slide in the share price when markets opened this morning.

The fall in sales revenue seems to have been caused by two factors: price cutting and a reduction in vouchers. These caused sales to fall by 2.2% and 2.4% respectively, compared to the same period last year. The result was that like-for-like transaction numbers fell by 2% and the average number of items per basket was 1.9% lower. These numbers suggest to me that Morrisons market share may still be falling, albeit slowly.

Should you invest £1,000 in Diageo right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Diageo made the list?

See the 6 stocks

There are some signs of progress. Morrisons said that net debt at the end of the year is expected to be below the previous target range of £1.9bn–£2.1bn. I take this to mean that cash flow remains strong and the forecast 5.2p dividend is safe.

Morrisons shares now trade on a forecast P/E of 18, falling to 15.5 for 2016/17. The prospective yield of 3% is useful but not outstanding. Overall, I’d say the shares are fully priced at the moment.

Cobham

Engineering firm Cobham warned this morning that full-year profits are likely to be at the lower end of expectations. This isn’t as bad as the full-blown profit warnings recently delivered by Cobham’s peers Meggitt and Chemring, but it’s not great news.

Once again, the problem seems to be poor earnings visibility. Demand has been weaker than expected from the oil sector and from clients in the Asia-Pacific region. Cobham’s revised earnings guidance suggests that adjusted earnings per share for the current year will be around 20p. This gives a forecast P/E of 14 at the current share price of 280p.

In my view, this valuation is ample. I wouldn’t buy Cobham shares at the moment, because there’s no reason to think that trading conditions will improve in the immediate future.

Hikma Pharmaceuticals

Shares in Hikma fell by around 5% on Monday, after the firm said that full-year sales of its generic medicines were likely to be below expectations.

Hikma said that sales of its colchicine gout treatment, sold under the Mitigare brand name, have been slower than expected. Generic sales are now expected to total $150m in 2015, a reduction from previous guidance of $175-$200m.

The generics business is the smallest of Hikma’s three divisions and generated just $79m of sales during the first half of this year, compared to $344m from injectables and $282m from branded products.

However, investors may be concerned that generics business is in terminal decline. Generic sales were $268m in 2013, $216m in 2014 and are expected to be just $150m in 2015. Profit margins are also falling. Last year, generics generated an adjusted operating margin of 52.3%. This year, that figure is expected to fall into “the high twenties”.

This decline could put pressure on Hikma’s earnings per share. The firm’s stock currently trades on a 2015 forecast P/E of 24, falling to 21 in 2016. Although Hikma does have a strong track record of growth, I don’t see this is as a compelling buy.

But this isn’t the only opportunity that’s caught my attention this week. Here are:

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares of Wm Morrison Supermarkets. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing For Beginners

Why I’m staying away from the Barclays share price even with a 19% drop

Jon Smith explains why he's cautious right now about the Barclays share price, with the potential for lower revenues from…

Read more »

Investing Articles

2 FTSE 100 and FTSE 250 stocks to consider as stock markets plummet!

Looking for lifeboats as growth-crushing trade tariffs loom? Here are two (including a FTSE 100 gold stock) I think merit…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

Just released: the 3 best growth-focused stocks to consider buying in April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Happy young plus size woman sitting at kitchen table and watching tv series on tablet computer
Investing Articles

£10,000 invested in Watches of Switzerland shares 1 year ago is now worth…

Watches of Switzerland shares have been decimated by Trump’s tariffs on Switzerland. Dr James Fox explores whether this is an…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Investing Articles

Growth stocks are crashing! Here’s what I’m doing now

Our writer shares his thoughts as growth stocks get crushed, as well as a favourite from the Nasdaq that he…

Read more »

Investing Articles

What’s going on with the Nvidia share price now?

The Nvidia share price is tanking. Once the most valuable listed company, Nvidia has seen more than $1trn wiped off…

Read more »

Investing Articles

This FTSE AIM stock has £2.3bn in net cash, and a market cap of £2.4bn!

I love this FTSE AIM stock, but it really hasn’t delivered for me yet. The stock trades with crazily low…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Down 15% in a week! Are these 5 FTSE 100 fallers screaming buys as markets plunge?

Five of Harvey Jones's favourite FTSE 100 stocks all have the same thing in common – they've fallen around 15%…

Read more »